David Humphreys

Company: UCB

Job title: Executive Director & Head of Antibody & Novel Therapeutics

Seminars:

8:30 am Fc & its Partners: FcR’s & Complement. Interacting Biology’s Leading to Receptor Inhibitors & Improvements to IgG’s as Drugs 8:57 am

Overview of FcRn biology and FcRn inhibitors FcRn and antibody half-life modulation Albumin as a focus for drug half-life Overlapping biology, complications, and opportunitiesRead more

day: Conference Day One